Avanci Launches 5G Connected Vehicle Licensing Program
16.8.2023 14:00:00 EEST | Business Wire | Press release
Avanci, the independent global leader in joint licensing solutions, today announced the launch of its 5G Connected Vehicle program that will simplify the licensing of the cellular technologies used in next generation connected vehicles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230816648734/en/
Avanci 5G Vehicle launches to simplify licensing of cellular technologies for next generation connected vehicles. (Graphic: Avanci)
Kasim Alfalahi, founder and Chief Executive Officer of Avanci, said: “Avanci was created with a vision of transforming how technology is shared. We ensure that the work of thousands of inventors around the world is recognized and rewarded. At the same time, by simplifying technology access, we enable companies to build exciting new products that are improving the lives of people across the globe, every day.”
The Avanci 5G Vehicle program covers patented technologies essential for 5G, 4G, 3G and 2G connectivity, including cellular vehicle-to-everything (C-V2X) which enables vehicles to directly communicate with other vehicles, cyclists, pedestrians, and transportation infrastructure.
Laurie Fitzgerald, Senior Vice President at Avanci, said: “The launch of our 5G Connected Vehicle program is an important milestone for Avanci, as we can now provide automakers with the efficient option of a single agreement, covering patented cellular technologies from dozens of organizations worldwide, to support the roll-out of 5G in connected vehicles. We appreciate the confidence and trust of all the partners who worked with us to create this new program and we are proud to make it a reality.”
This new Avanci program builds on the success of Avanci 4G Vehicle, which today has more than 130 million connected vehicles on the world’s roads from more than 80 automotive brands covered by an Avanci 4G Vehicle license.
Roger Lanctot, Director, Automotive Connected Mobility at TechInsights said, “The transition from 4G technology to 5G will be unlike any prior wireless changeover. For the first time, automakers are facing an industry transformation touching all aspects of vehicle development and sales, and car ownership. With 25 global automakers committed to deployment, prospects are bright for 5G to transform vehicle connectivity. TechInsights forecasts that the share of 5G connected vehicles will grow to over 50% of new vehicle production in 5 years’ time.”
Avanci launches this new program with a license that covers thousands of patented technologies essential for implementing cellular connectivity. Details of the Avanci 5G Vehicle program, including the 59 initial participants, together with terms including early adopter pricing for licensees, can be found at avanci.com/5Gvehicle.
About Avanci
Avanci believes that sharing patented technology can be simpler. An independent intermediary not owned or controlled by licensors or licensees, Avanci works at the intersection of different industries. Our one-stop solutions are designed to bring efficiency, convenience, and predictability to the licensing process. Since 2016, Avanci has been driving innovation forward by making connections through our licensing platforms. Avanci is proud to be a part of the World Economic Forum’s Global Innovators Community.
www.avanci.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230816648734/en/
Contact information
Avanci
Mark Durrant
Vice President, Marketing & Communications
media@avanci.com
+1 (469) 480-2558 / +44 7875 276867
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom